83.21
Henry Schein Inc stock is traded at $83.21, with a volume of 970.30K.
It is down -0.54% in the last 24 hours and down -6.36% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
See More
Previous Close:
$83.66
Open:
$79.95
24h Volume:
970.30K
Relative Volume:
0.80
Market Cap:
$9.27B
Revenue:
$13.38B
Net Income/Loss:
$418.00M
P/E Ratio:
25.13
EPS:
3.3112
Net Cash Flow:
$391.00M
1W Performance:
-2.03%
1M Performance:
-6.36%
6M Performance:
+10.17%
1Y Performance:
+28.55%
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC vs MCK, COR, CAH, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
HSIC
Henry Schein Inc
|
83.21 | 9.27B | 13.38B | 418.00M | 391.00M | 3.3112 |
|
MCK
Mckesson Corp
|
917.77 | 107.00B | 403.43B | 5.10B | 5.41B | 38.47 |
|
COR
Cencora Inc
|
315.48 | 60.20B | 328.68B | 2.55B | 1.56B | 13.03 |
|
CAH
Cardinal Health Inc
|
232.95 | 53.94B | 250.74B | 1.55B | 4.39B | 6.5398 |
|
AHG
Akso Health Group Adr
|
1.1995 | 1.03B | 14.85M | -136.07M | 7.25M | -0.4726 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-26 | Initiated | BMO Capital Markets | Market Perform |
| Jun-11-26 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-16-26 | Initiated | BTIG Research | Neutral |
| Apr-15-26 | Initiated | Citigroup | Buy |
| Feb-23-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
Henry Schein, Inc. (HSIC) Options Chain - Yahoo! Finance Canada
HSIC or MMSI: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Henry Schein Celebrates 20 Years of Practice Pink - Dentistry Today
Should Value Investors Buy Henry Schein (HSIC) Stock? - Zacks Investment Research
Should Value Investors Buy Henry Schein (HSIC) Stock? - Yahoo Finance
Henry Schein Marks 20th Anniversary of Practice Pink Initiative - Orthodontic Products
Henry Schein expands credit line while analysts rate Henry Schein stock Moderate Buy - AD HOC NEWS
Henry Schein Inc. stock outperforms competitors on strong trading day - MarketWatch
Henry Schein Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Henry Schein Cares Marks 25 Years of Helping Health Happen® - Eagle-Tribune
Henry Schein Cares Marks 25 Years of Helping Health Happen® - Business Wire
Henry Schein Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Henry Schein (HSIC): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
Henry Schein stock reflects raised 2026 guidance at USD 86.37 - AD HOC NEWS
Ex-Henry Schein manager gets jail for major embezzlement - DrBicuspid.com
Henry Schein Inc Lobbying Profile, 2011 - OpenSecrets
Henry Schein credit supervisor sentenced to prison for embezzling $1.6M from Melville company - Newsday
Henry Schein Q2FY26 Results: Non-GAAP EPS up 15.5%, guidance raised - scanx.trade
Transcript: Henry Schein Q2 2026 Earnings Conference Call - Benzinga
Is Henry Schein Stock Outperforming the Dow? - finance.yahoo.com
Is Henry Schein Stock Outperforming the Dow? - inkl
Henry Schein stock trades below its yearly high after Q2 figures - AD HOC NEWS
Henry Schein stock heads into the open after closing at USD 85.05 - AD HOC NEWS
Henry Schein stock trades at USD 85.56 after Q2 guidance - AD HOC NEWS
Henry Schein, Inc. (HSIC) Stock Forecasts - Yahoo Finance
Henry Schein Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Henry Schein Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Henry Schein stock gains 0.42 percent ahead of the open - AD HOC NEWS
Henry Schein, Inc. Amends and Restates $1 Billion Revolving Credit Agreement to Increase Commitments to $1.25 Billion - marketscreener.com
Henry Schein Expands Revolving Credit Facility to $1.25 Billion, Extends Maturity to 2031 - TradingView
Henry Schein, Inc. (HSIC) Stock Analysis: A Promising 15.73% Upside in the Healthcare Sector - DirectorsTalk Interviews
Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher (NASDAQ:HSIC) - Seeking Alpha
Henry Schein (HSIC) Q1 2026 Earnings Call Transcript - Fortune
Henry Schein Prepares to Report Q2 Earnings: What's in the Cards? - Eastern Progress
Are Investors Undervaluing Henry Schein (HSIC) Right Now? - Yahoo Finance
What Makes Henry Schein (HSIC) a New Buy Stock - Yahoo Finance
Henry Schein, Inc. (HSIC) Stock Analysis: Exploring an 11.12% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Henry Schein Inc Share PriceHSIC, RNS News, Articles, Quotes, & Charts (NASDAQ:HSIC) - Proactive financial news
Henry Schein stock holds firm after a fresh target lift - ad-hoc-news.de
Henry Schein stock heads into the open after a 1.0% daily loss - ad-hoc-news.de
Henry Schein Executive Andrea Albertini Reports Two Stock Disposals on September 8, 2026 - Kalkine Media
Tax withholding prompts Henry Schein (HSIC) insider to return shares - Stock Titan
Henry Schein stock holds steady after recent earnings update - ad-hoc-news.de
Henry Schein Inc. stock outperforms competitors despite losses on the day - MarketWatch
Precision Trading with Henry Schein Inc. (HSIC) Risk Zones - Stock Traders Daily
Henry Schein stock rises on a new distribution deal - ad-hoc-news.de
Henry Schein to Present at Baird Global Healthcare Conference - dentistrytoday.com
Henry Schein to Distribute Applied BioCode's MDx-3000 System in US - marketscreener.com
Applied BioCode Announces Distribution Agreement with Henry Schein - Business Wire
Henry Schein to Participate in Upcoming Investor Conference in September - Business Wire
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Henry Schein Inc Stock (HSIC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HERRING JOSEPH L | Former Director |
Jun 30 '26 |
Proposed Sale |
84.29 |
28,791 |
2,426,793 |
0 |
| Stanley M. Bergman | Affiliate |
Jun 16 '26 |
Proposed Sale |
81.09 |
16,933 |
1,373,097 |
0 |
| DANIEL WILLIAM K | Director |
May 11 '26 |
Buy |
69.19 |
10,000 |
691,900 |
20,000 |
| Popeck Thomas C | CEO, Henry Schein Products |
Mar 19 '26 |
Sale |
72.79 |
1,355 |
98,630 |
86,182 |
| Popeck Thomas C | Officer |
Mar 19 '26 |
Proposed Sale |
72.79 |
1,355 |
98,630 |
0 |
| KUEHN KURT P | Director |
Mar 10 '26 |
Proposed Sale |
78.96 |
2,844 |
224,565 |
0 |
| KUEHN KURT P | Director |
Mar 10 '26 |
Sale |
78.96 |
2,844 |
224,565 |
15,420 |
| LASKAWY PHILIP A | Director |
Mar 05 '26 |
Proposed Sale |
80.36 |
2,844 |
228,544 |
0 |
| LASKAWY PHILIP A | Director |
Mar 05 '26 |
Sale |
80.36 |
2,844 |
228,544 |
21,961 |
| MLOTEK MARK E | Officer |
Mar 04 '26 |
Proposed Sale |
80.80 |
5,925 |
478,739 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):